MONTREAL, Aug. 16, 2005 (PRIMEZONE) -- Viropro, Inc. (OTCBB:VPRO) today announced the promotion of Mr. Rinaldo Cesar Mancin to the position of Vice-President - Business Development of Viropro Canada Inc. In this new position, Mr. Mancin will continue to build both of the core businesses of Viropro which appear to be emerging stronger than anticipated.
The Life Sciences' business which focuses on Bio-Generics, will remain within Viropro Pharma, Inc., a wholly owned subsidiary. To date, the Company has had a number of successful discussions with potential partners in several countries, the results of which could exceed original expectations. The Company expects to conclude many of these relationships and announce developments next month.
The natural consumer products business, referred to as Nutraceuticals, has also witnessed major advancements both domestically and internationally. As such, its potential is projecting to surpass original forecasts. Accordingly, this month, the Company plans to spin off this business from Viropro Pharma into a separate, wholly owned subsidiary.
Mr. Mancin currently serves in a similar capacity for Viropro Pharma. With over 15 years experience in project management in Brazil and an impressive portfolio of private and institutional contacts, Mr. Mancin brings critical expertise to Viropro in the implementation of strategies aimed at the successful penetration of developing markets. This appointment provides the company with stronger management support for the implementation of its business activities worldwide and is expected to further boost the Company's development in Latin America, Africa and Asia, which appears to be exceeding expectations.
Mr. Mancin is a former Executive Secretary for the National Genetic Resources Council in Brazil, where he played a key role in development and implementation of policies in the biotechnological sector. Mr. Mancin has also acted as Chief Negotiator for environmental and biotechnological projects on behalf of the Brazilian government with a number of prestigious international agencies, including the Convention on Biological Diversity (CBD), the World Intellectual Property Organization (WIPO), and the World Trade Organization (WTO).
About Viropro, Inc.
Viropro, Inc. (www.viropropharma.com) is establishing a growth portfolio in Life Sciences markets through strategic alliances and revenue-producing acquisitions with the potential for continued shareholder value.
Viropro, Inc.'s Safe Harbor Statement
Except for any historic information contained herein, the matters discussed in this press release contain forward-looking statements that involve risks and uncertainties, which are subject to section 27A of the Securities Act of 1933 and section 21E of the Exchange Act of 1934, and are subject to safe harbor created by these sections. Any statements that express or involve discussions with respect to predictions, beliefs, plans, projections, objectives, goals, assumptions of future events or performances are not statements of historical fact and may be "forward looking statements". Forward looking statements in this release may be identified through the use of such words as "expects", "anticipates", "estimates", "believes", or statements indicating certain actions "may", "could", or "might" occur. Actual results, performance or achievements could differ materially from those anticipated in such forward-looking statements, which involve numerous risks and uncertainties, including the Company's ability to market its products and services in a competitive environment as well as other factors.